VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
ORKA
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
ORKAOruka Therapeutics, Inc.
$96.32$5.8B
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
  1. Home
  2. Financial Ratios

  1. Home
  2. Stocks
  3. ORKA
  4. Financial Ratios

Oruka Therapeutics, Inc. (ORKA) Financial Ratios

Latest Ratios: P/E Ratio -45.2x · EV/EBITDA N/A · ROE -24.7%. (2005–2025 historical series)

Income StatementBalance SheetCash FlowRatios
AnnualQuarterly

ORKA Valuation Multiples

Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Market Cap$5.8B$1.4B$326M$294M$410M$359M$227M$8M$5M$14M$26M
Enterprise Value$5.8B$1.3B$265M$257M$368M$306M$178M$-793811$-2037883$5M$18M
P/E Ratio →-45.20——————————
P/S Ratio———————————
P/B Ratio9.312.930.857.949.837.034.870.990.761.371.16
P/FCF———————————
P/OCF———————————

P/E links to full P/E history page with 30-year chart

ORKA EV Ratios

Enterprise-value multiples — capital-structure-neutral measures of total business value

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
EV / Revenue———————————
EV / EBITDA———————————
EV / EBIT———————————
EV / FCF———————————

ORKA Profitability

Margins and return-on-capital ratios measuring operating efficiency

Margins

Full margin charts and quarterly trend are on the Earnings History page

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Gross Margin———————————
Operating Margin———————————
Net Profit Margin———————————

Return on Capital

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
ROE-24.7%-24.7%-39.9%-13.6%-21.4%-39.6%-36.0%-80.4%-97.3%-113.9%-54.6%
ROA-23.8%-23.8%-38.6%-13.2%-20.3%-36.7%-33.0%-71.4%-82.7%-100.0%-51.2%
ROIC-24.5%-24.5%-41.1%—————-1221.4%-171.5%-177.2%
ROCE-28.5%-28.5%-41.9%-18.4%-21.1%-39.3%-35.8%-85.2%-99.4%-115.1%-55.1%

ORKA Leverage & Debt

Solvency and debt-coverage ratios — lower is generally safer

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Debt / Equity0.000.000.000.010.010.010.010.00———
Debt / EBITDA———————————
Net Debt / Equity—-0.10-0.16-1.00-1.01-1.04-1.05-1.10-1.10-0.85-0.33
Net Debt / EBITDA———————————
Debt / FCF———————————
Interest Coverage——-56.03———-1082.00-806.00———

Net cash position: cash ($47M) exceeds total debt ($2M)

ORKA Liquidity & Efficiency

Short-term solvency ratios and asset-utilisation metrics

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Current Ratio22.3722.3728.8959.0137.7215.5614.289.168.555.948.95
Quick Ratio22.3722.3728.8959.0137.7215.5614.289.168.555.948.95
Cash Ratio21.9221.9228.8058.7637.5015.2514.029.038.335.688.83
Asset Turnover———————————
Inventory Turnover———————————
Days Sales Outstanding———————————

ORKA Shareholder Yields

Earnings, FCF, buyback, and dividend yields — total returns to shareholders

Dividends

Full dividend history and growth charts are on the Dividend History page

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Dividend Yield———————————
Payout Ratio———————————

Total Shareholder Return Metrics

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Earnings Yield———————————
FCF Yield———————————
Buyback Yield0.0%0.0%0.0%—0.0%0.0%0.0%0.0%0.0%0.0%0.0%
Total Shareholder Yield0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%
Shares Outstanding—$46M$17M$14M$14M$14M$5M$110102$64115$48293$41978

Key Metrics

Growth RegimeMixed
ProfitabilityNegative
Balance SheetMixed
Cash FlowBurning
Top Statement Risk

Dilutive financing dependence risk

Multiples Not Meaningful for Pre-Revenue Stage

Based on reported figures, ORKA trades at a P/E of -49.43 and a P/B of 10.18, with EV/EBITDA and P/S unavailable, so earnings-based multiples offer little guidance while the book multiple signals the market is paying a steep premium over tangible net assets.

The negative P/E reflects a net loss rather than a comparable earnings base, so it cannot be benchmarked against peers such as REGN at 20.94 in any meaningful way. The P/B of 10.18 versus REGN at 3.32 and ARQT at 18.98 suggests the market is pricing ORKA's pipeline and platform optionality well above its book value, which may indicate a platform premium rather than current fundamentals. Investors should monitor how this premium holds as clinical data arrives and the equity base continues to expand through financing.

Returns Improving Slightly Off Deep Trough

According to recent SEC filings, ORKA's ROE moved from -65.7% in 2024Q2 to -4.3% in 2026Q3, while ROIC has hovered near -5% to -6%, a pattern that reflects a rapidly enlarged equity base rather than improving operating economics.

The apparent convergence of ROE toward zero is largely mechanical, since equity grew from a small base to roughly $1.2B while losses expanded in absolute terms. ROIC remaining negative in the mid-single digits suggests capital is being deployed into clinical development without yet generating returns, which is expected for the stage. The improvement in ROE should therefore not be read as compounding; it may simply reflect the denominator effect of recent equity raises.

Minimal Debt Keeps Leverage Risk Contained

As reported in financial statements, ORKA's debt-to-equity ratio sits at roughly 0.00 across recent quarters, with interest coverage unavailable, indicating that leverage is not the binding constraint on the balance sheet.

With total debt of about $2.9M against roughly $1.2B in equity, the capital structure is overwhelmingly equity-funded, which removes covenant and refinancing risk from the near-term picture. Interest coverage cannot be meaningfully computed given the absence of operating earnings. The more relevant balance sheet pressure is the funding requirement itself rather than debt service, which warrants monitoring as spending continues.

Current Ratio Strong but Cash Burn Dominates

Based on reported figures, ORKA's current ratio fell from 38.51 in 2026Q2 to 29.62 in 2026Q3 and the quick ratio mirrors it, yet a quarterly operating outflow near $44.3M suggests these high ratios may overstate durable liquidity.

The current and quick ratios are nearly identical, consistent with a balance sheet dominated by cash and short-term holdings with negligible inventory. The decline from the prior quarter indicates that current liabilities or cash consumption are rising faster than the liquid asset base in relative terms. Liquidity should be assessed against the burn rate rather than the ratio itself, since the current ratio alone does not reveal how many quarters of operations the cash balance can support.

Asset-Light Ratios Obscure Financing Dependence

The ratio most commonly misapplied to ORKA is the current ratio, which appears strong at 29.62 yet ignores the cumulative cash burn exceeding $260M across ten quarters that the company has funded largely through external capital.

Because ORKA carries almost no inventory or receivables, standard working-capital ratios such as the current ratio and DSO offer little insight into operating health and can create a misleadingly comfortable picture. A more informative lens is cash runway measured as cash divided by quarterly operating burn, which on reported figures is well under two quarters at the latest run rate. Investors should weigh this runway metric and the pace of dilution more heavily than headline liquidity ratios.

Download Financial Ratios Data

Includes 30+ ratios · 21 years · Updated daily

Consensus & Technical Research Suite
Open ORKA Terminal

ORKA Chart Terminal

WASM

Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.

Launch Terminal

Live Breakouts Feed

LIVE

High-probability breakout stocks crossing their pivot across 5 pattern engines.

Explore Setups

Intrinsic Valuation

DCF models, multiple analysis, and analyst estimates.

Check Valuation

Historical Returns

10-year return with dividends reinvested.

Calculate

Peer Comparison

Compare growth, multiples, and margins vs sector.

Compare

ORKA — Frequently Asked Questions

Quick answers to the most common questions about buying ORKA stock.

What is Oruka Therapeutics, Inc.'s P/E ratio?

Oruka Therapeutics, Inc.'s current P/E ratio is -45.2x. This places it at the 50th percentile of its historical range.

What is Oruka Therapeutics, Inc.'s ROE?

Oruka Therapeutics, Inc.'s return on equity (ROE) is -24.7%. The historical average is -71.2%.

Is ORKA stock overvalued?

Based on historical data, Oruka Therapeutics, Inc. is trading at a P/E of -45.2x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.